Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors.


Journal

Angewandte Chemie (International ed. in English)
ISSN: 1521-3773
Titre abrégé: Angew Chem Int Ed Engl
Pays: Germany
ID NLM: 0370543

Informations de publication

Date de publication:
23 12 2022
Historique:
received: 01 09 2022
pubmed: 9 10 2022
medline: 17 12 2022
entrez: 8 10 2022
Statut: ppublish

Résumé

During our search for novel myxobacterial natural products, we discovered the thiamyxins: thiazole- and thiazoline-rich non-ribosomal peptide-polyketide hybrids with potent antiviral activity. We isolated four congeners of this unprecedented natural product family with the non-cyclized thiamyxin D fused to a glycerol unit at the C-terminus. Alongside their structure elucidation, we present a concise biosynthesis model based on biosynthetic gene cluster analysis and isotopically labelled precursor feeding. We report incorporation of a 2-(hydroxymethyl)-4-methylpent-3-enoic acid moiety by a GCN5-related N-acetyltransferase-like decarboxylase domain featuring polyketide synthase. The thiamyxins show potent inhibition of RNA viruses in cell culture models of corona, zika and dengue virus infection. Their potency up to a half maximal inhibitory concentration of 560 nM combined with milder cytotoxic effects on human cell lines indicate the potential for further development of the thiamyxins.

Identifiants

pubmed: 36208117
doi: 10.1002/anie.202212946
pmc: PMC10100342
doi:

Substances chimiques

RNA 63231-63-0
Polyketide Synthases 79956-01-7
Polyketides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202212946

Informations de copyright

© 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH.

Références

Eur J Med Chem. 2015 Jun 5;97:699-718
pubmed: 25934508
Angew Chem Int Ed Engl. 2021 Feb 8;60(6):3229-3237
pubmed: 33107670
Angew Chem Int Ed Engl. 2017 Aug 1;56(32):9614-9618
pubmed: 28590072
J Nat Prod. 2004 Dec;67(12):2141-53
pubmed: 15620274
ACS Med Chem Lett. 2017 Sep 18;8(10):1007-1012
pubmed: 29057042
Chem Biol. 2012 Mar 23;19(3):361-71
pubmed: 22444591
Acta Crystallogr C. 1994 Mar 15;50 ( Pt 3):432-4
pubmed: 8018309
Structure. 2020 Jan 7;28(1):63-74.e4
pubmed: 31785925
Science. 2007 Nov 9;318(5852):970-4
pubmed: 17991863
Nat Prod Rep. 2016 Feb;33(2):127-35
pubmed: 26175103
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Nat Chem Biol. 2020 Sep;16(9):1013-1018
pubmed: 32601484
J Am Chem Soc. 2022 Aug 10;144(31):14057-14070
pubmed: 35895935
Nat Prod Res. 2018 Aug;32(16):1926-1950
pubmed: 28748726
Nat Commun. 2019 Mar 29;10(1):1408
pubmed: 30926818
Org Biomol Chem. 2017 Nov 15;15(44):9372-9378
pubmed: 29090723
Antimicrob Agents Chemother. 1981 Apr;19(4):504-7
pubmed: 7247372
Front Genet. 2022 Mar 08;13:758715
pubmed: 35350244
Nat Commun. 2018 Feb 23;9(1):803
pubmed: 29476047
Appl Environ Microbiol. 2020 Jan 7;86(2):
pubmed: 31676482
J Am Chem Soc. 2008 Feb 13;130(6):1806-7
pubmed: 18205365
Nat Prod Rep. 2017 Feb 1;34(2):135-160
pubmed: 27907217
Drug Discov Today. 2021 Feb;26(2):593-603
pubmed: 33253920
ACS Chem Biol. 2016 Dec 16;11(12):3319-3327
pubmed: 27723289
Virus Res. 2020 Oct 15;288:198114
pubmed: 32800805
Nucleic Acids Res. 2020 Jan 8;48(D1):D265-D268
pubmed: 31777944
Chemistry. 2022 Feb 21;28(10):e202104484
pubmed: 34990513
PLoS One. 2012;7(3):e32857
pubmed: 22412934
J Am Chem Soc. 2001 Jun 13;123(23):5418-23
pubmed: 11389621
Acta Clin Belg. 2022 Apr;77(2):436-444
pubmed: 33090941
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):95-100
pubmed: 27994138
Nat Commun. 2022 Jan 10;13(1):62
pubmed: 35013184
J Antibiot (Tokyo). 1993 Nov;46(11):1752-5
pubmed: 8270498
Angew Chem Int Ed Engl. 2022 Dec 23;61(52):e202212946
pubmed: 36208117
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954

Auteurs

Patrick A Haack (PA)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Kirsten Harmrolfs (K)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Chantal D Bader (CD)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Ronald Garcia (R)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Antonia P Gunesch (AP)

Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.
German Center for Infection Research, Hannover-Braunschweig Partner Site, and Cluster of Excellence RESIST (EXC 2155), Hannover, Germany.

Sibylle Haid (S)

Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.
German Center for Infection Research, Hannover-Braunschweig Partner Site, and Cluster of Excellence RESIST (EXC 2155), Hannover, Germany.

Alexander Popoff (A)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Alexander Voltz (A)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Heeyoung Kim (H)

Department of Infectious Diseases, Molecular Virology, Heidelberg University, German Center for Infection Research, Heidelberg Partner Site and Division of Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), German Center for Infection Research (DZIF), Heidelberg, Germany.

Ralf Bartenschlager (R)

Department of Infectious Diseases, Molecular Virology, Heidelberg University, German Center for Infection Research, Heidelberg Partner Site and Division of Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), German Center for Infection Research (DZIF), Heidelberg, Germany.

Thomas Pietschmann (T)

Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.
German Center for Infection Research, Hannover-Braunschweig Partner Site, and Cluster of Excellence RESIST (EXC 2155), Hannover, Germany.

Rolf Müller (R)

Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
German center for infection research (DZIF), Braunschweig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH